Results (
English) 1:
[Copy]Copied!
The DPPH∙ active EAF (17.2 g) was loaded as a dried slurry of silica gel to column chromatography (45 × 3.5 cm) and eluted with petroleum ether: EtOAc gradient elution (100 : 0—0 : 100), in increasing order of polarity. A total of 92 fractions of 100mL each were collected and analyzed by TLC (Silica gel F254 plates 20 × 20cm, Merck, Germany). TLC analysis was carried out using ethyl acetate: chloroform: formic acid (5:4:1) as the mobile phase and the separated bands were visualized using iodine vapors and vanillin-sulphuric acid reagent. These fractions were pooled to afford seven major fractions (Fr. A: 1–13, Fr. B: 14–35, Fr. C: 36–48, Fr. D: 49–60, Fr. E: 61–70, Fr. F: 71–80, and Fr. G: 81–92) based on TLC analysis. These fractions were tested for bioactivity using DPPH spectrophotometric assay.For further purification, the highly active Fr. B (2.8 g) was loaded on a silica gel column, eluted with petroleum ether- EtOAc gradients, and the ethyl acetate content of themixture was increased in a series of 5% steps. The inactive and less active proved fractions were discarded. Finally, the active Fr.B2 eluted with petroleum ether-ethyl acetate (85 : 15) yielded 117mg of compound. The purity of isolated compound was establishedbyHPLCandits structurewas confirmed through the interpretation of the spectral data (UV, FT-IR, 1H, 13C NMR, and MS) and further tested for its antioxidant effects.
Being translated, please wait..
